CN111670187B - β-内酰胺酶抑制剂及其用途 - Google Patents

β-内酰胺酶抑制剂及其用途 Download PDF

Info

Publication number
CN111670187B
CN111670187B CN201980010129.1A CN201980010129A CN111670187B CN 111670187 B CN111670187 B CN 111670187B CN 201980010129 A CN201980010129 A CN 201980010129A CN 111670187 B CN111670187 B CN 111670187B
Authority
CN
China
Prior art keywords
octane
cyclopropane
oxo
bicyclo
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980010129.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111670187A (zh
Inventor
吴予川
黄少强
陈曦
胡永韩
刘霄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Sinoway Pharmaceutical Technology Co ltd
Original Assignee
Suzhou Sinovent Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Sinovent Pharmaceuticals Co Ltd filed Critical Suzhou Sinovent Pharmaceuticals Co Ltd
Publication of CN111670187A publication Critical patent/CN111670187A/zh
Application granted granted Critical
Publication of CN111670187B publication Critical patent/CN111670187B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980010129.1A 2018-01-25 2019-01-24 β-内酰胺酶抑制剂及其用途 Active CN111670187B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/074185 2018-01-25
CN2018074185 2018-01-25
PCT/CN2019/073000 WO2019144912A1 (zh) 2018-01-25 2019-01-24 β-内酰胺酶抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN111670187A CN111670187A (zh) 2020-09-15
CN111670187B true CN111670187B (zh) 2021-04-16

Family

ID=67394549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980010129.1A Active CN111670187B (zh) 2018-01-25 2019-01-24 β-内酰胺酶抑制剂及其用途

Country Status (8)

Country Link
US (1) US11078202B2 (enExample)
EP (1) EP3744722A4 (enExample)
JP (1) JP7273420B2 (enExample)
KR (1) KR102769880B1 (enExample)
CN (1) CN111670187B (enExample)
AU (1) AU2019211693B2 (enExample)
CA (1) CA3089150A1 (enExample)
WO (1) WO2019144912A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102769880B1 (ko) 2018-01-25 2025-02-20 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. β-락타마제 억제제 및 그 용도
CA3238268A1 (en) 2021-11-17 2023-05-25 Xufan WANG ?-lactamase inhibitor intermediate and preparation method therefor
CN117186107A (zh) * 2022-05-31 2023-12-08 成都先导药物开发股份有限公司 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法
WO2024160247A1 (zh) 2023-02-02 2024-08-08 苏州信诺维医药科技股份有限公司 含β-内酰胺酶抑制剂的药物组合物及其应用
CN116730941B (zh) * 2023-06-15 2024-07-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 5-苯基-1,3,4-恶二唑类化合物及其制备方法和应用
CN118453513B (zh) * 2024-05-23 2025-06-17 苏州信诺维医药科技股份有限公司 一种β-内酰胺酶抑制剂液体制剂的制备工艺

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918407A (zh) * 2008-01-18 2010-12-15 默沙东公司 β-内酰胺酶抑制剂
CN103649088A (zh) * 2011-08-30 2014-03-19 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
CN104334555A (zh) * 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 异噁唑β-内酰胺酶抑制剂
WO2015150890A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1098129A (en) 1910-04-05 1914-05-26 John Thomas Simpson Aeroplane.
US1033000A (en) 1910-12-14 1912-07-16 Joseph Leslie Forster Pneumatic piano-player.
US1337809A (en) 1917-06-22 1920-04-20 Winton Alexander Protecting means for vessels
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
CN106211771A (zh) 2014-01-21 2016-12-07 沃克哈特有限公司 含氮化合物及其作为抗菌剂的用途
EP3131583A1 (en) 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
WO2015173663A1 (en) 2014-05-14 2015-11-19 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester
WO2015173665A1 (en) 2014-05-14 2015-11-19 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate
CN108137567A (zh) 2015-10-02 2018-06-08 乐高化学生物科学股份有限公司 用于抑制β-内酰胺酶的组合物和方法
KR102769880B1 (ko) 2018-01-25 2025-02-20 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. β-락타마제 억제제 및 그 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918407A (zh) * 2008-01-18 2010-12-15 默沙东公司 β-内酰胺酶抑制剂
CN103649088A (zh) * 2011-08-30 2014-03-19 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
CN104334555A (zh) * 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 异噁唑β-内酰胺酶抑制剂
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
WO2015150890A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester

Also Published As

Publication number Publication date
KR20200113247A (ko) 2020-10-06
US11078202B2 (en) 2021-08-03
WO2019144912A1 (zh) 2019-08-01
CN111670187A (zh) 2020-09-15
CA3089150A1 (en) 2019-01-24
US20210032260A1 (en) 2021-02-04
AU2019211693A1 (en) 2020-09-03
JP2021511351A (ja) 2021-05-06
AU2019211693B2 (en) 2023-12-21
JP7273420B2 (ja) 2023-05-15
EP3744722A4 (en) 2021-11-03
EP3744722A1 (en) 2020-12-02
KR102769880B1 (ko) 2025-02-20

Similar Documents

Publication Publication Date Title
KR102769880B1 (ko) β-락타마제 억제제 및 그 용도
TWI773687B (zh) β內醯胺酶抑制劑化合物
TWI659953B (zh) 經脒取代之β－內醯胺化合物，其製備及用途
US10934295B2 (en) Antimicrobials and methods of making and using same
CN110312722A (zh) 抗微生物剂及其制备和使用方法
RU2737892C1 (ru) Гидроксиалкилтиадиазольные производные
TWI829686B (zh) 氧基取代化合物
US8841306B2 (en) Antimicrobials
CN102171207B (zh) 带有环状偕胺肟或环状脒腙的噁唑烷酮衍生物及其药物组合物
RU2162088C2 (ru) 1-метилкарбапенем или его фармакологически приемлемые соли, композиция, способ предупреждения или лечения бактериальных инфекций
JP2023505885A (ja) 単環β－ラクタム化合物及びその使用
US20060247286A1 (en) Oxazolidinone antibiotics and derivatives thereof
CN104098588B (zh) 一类三环喹诺酮衍生物及其制备方法和用途
WO1996001261A1 (en) Novel carbapenem derivative
US20210046057A1 (en) Beta-lactamase inhibitor and use thereof
WO2017189866A1 (en) Polymyxin analogs useful as antibiotic potentiators
CN115605480B (zh) 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
KR20000048687A (ko) 피리도벤족사진 유도체
CN111196808B (zh) 二氮杂双环类化合物及其应用
HK40120313A (en) 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors
JP2004203809A (ja) 新規ビフェニル誘導体
HK40070082B (en) 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors
TW202038941A (zh) 烷基取代化合物
HK1018260B (en) A 1-methylcarbapenem derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: Suzhou Sinoway Pharmaceutical Technology Co.,Ltd.

Address before: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee before: Suzhou Sinovent Pharmaceuticals Co.,Ltd.